M
Maarten H. Vermeer
Researcher at Leiden University Medical Center
Publications - 208
Citations - 14379
Maarten H. Vermeer is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Mycosis fungoides & Lymphoma. The author has an hindex of 54, co-authored 192 publications receiving 12774 citations. Previous affiliations of Maarten H. Vermeer include Leiden University & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
WHO-EORTC classification for cutaneous lymphomas.
Rein Willemze,Elaine S. Jaffe,Günter Burg,Lorenzo Cerroni,Emilio Berti,Steven H. Swerdlow,Elisabeth Ralfkiaer,Sergio Chimenti,José Luis Diaz-Perez,Lyn M. Duncan,Florent Grange,Nancy L. Harris,Werner Kempf,Helmut Kerl,Michael O. Kurrer,Robert Knobler,Nicola Pimpinelli,Chris Sander,Marco Santucci,Wolfram Sterry,Maarten H. Vermeer,Janine Wechsler,Sean Whittaker,Chris J.L.M. Meijer +23 more
TL;DR: The characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin are described, and differences with the previous classification schemes are discussed.
Journal ArticleDOI
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
Rein Willemze,Patty M. Jansen,Lorenzo Cerroni,Emilio Berti,Marco Santucci,Chalid Assaf,Marijke R. Canninga-van Dijk,Agnes Carlotti,M.L. Geerts,Sonja Hahtola,Michael Hummel,Leila Jeskanen,Werner Kempf,Cesare Massone,Pablo L. Ortiz-Romero,Marco Paulli,Tony Petrella,Annamari Ranki,José L. Rodriguez Peralto,Alistair Robson,Nancy J. Senff,Maarten H. Vermeer,Janine Wechsler,Sean Whittaker,Chris J.L.M. Meijer +24 more
TL;DR: SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned, while SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4-, CD8-, CD56+/-, betaF1- T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment.
Journal ArticleDOI
Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior
Emilio Berti,Dario Tomasini,Maarten H. Vermeer,Chris J.L.M. Meijer,Elvio Alessi,Rein Willemze +5 more
TL;DR: In this article, the clinical, histological, and immunophenotypical features of 17 CD8+ CTCL were reviewed, and the results indicated that these strongly epidermotropic primary cutaneous CD8+, cytotoxic T cell lymphomas represent a distinct type of CTCCL with an aggressive clinical behavior.
Journal ArticleDOI
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
Nancy J. Senff,Evert M. Noordijk,Youn H. Kim,Martine Bagot,Emilio Berti,Lorenzo Cerroni,Reinhard Dummer,Madeleine Duvic,Richard T. Hoppe,Nicola Pimpinelli,Steven T. Rosen,Maarten H. Vermeer,Sean Whittaker,Rein Willemze +13 more
TL;DR: Uniform recommendations for the management of the 3 main groups of primary cutaneous B-cell lymphomas are provided to contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
Journal ArticleDOI
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Werner Kempf,Katrin Pfaltz,Maarten H. Vermeer,Antonio Cozzio,Pablo L. Ortiz-Romero,Martine Bagot,Elise A. Olsen,Youn H. Kim,Reinhard Dummer,Nicola Pimpinelli,Sean Whittaker,Emmilia Hodak,Lorenzo Cerroni,Emilio Berti,Steve Horwitz,H. Miles Prince,Joan Guitart,Teresa Estrach,José Antonio Sanches,Madeleine Duvic,Annamari Ranki,Brigitte Dréno,Sonja Ostheeren-Michaelis,Robert Knobler,Gary S. Wood,Rein Willemze +25 more
TL;DR: Recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30 (+) L PDs.